Yesterday did not get any better and this is certainly not the start to the ASCO run up that the sector would want. That being said there was so little news yesterday, it is not completely surprising that the sector could not break free from the macro worries (Greece and dollar seemed to be the […]
13F Analysis of Best Performing Healthcare Hedge Funds (Q1 2015)
13F filings have arrived and it’s like Christmas day for me. I’ve been pouring through the filings, tweeting the interesting ones, and probably annoying everyone on twitter. These filings are a great idea generation tool, a starting place for due diligence, and way to get a peek at the focus of the best minds in […]
May 21 Biotech Update
It is a similar start to the trading day with the market sort of flat with the sector a little lower (with notable exceptions which will be discussed below). It was encouraging yesterday that the sector got stronger throughout the day. We were stuck in a pattern with gap higher in the morning and then […]
May 19 Biotech Update
A mixed start to the morning with some red and green. It seems to me that the market generally wants to move higher but no one seems to have high conviction with that move. I am like everyone else looking for the next shoe to drop and not really trusting the rally. That very well […]
May 18th Biotech Update
The sector seems to be treading water this morning if not slightly outperforming the broader market. There seems to be a tug of war of wanting to be positioned into the potential run ups into ASCO (and EHA) and potential deal flow but the fear of being the last one holding when the sector corrects. […]
May 8 Biotech Update
I wish I had more time to write this week but it has been too busy. The sector is obviously doing well and perhaps we have bottomed but at the very least we are set for a relief rally. Perhaps if we can get some additional M&A Monday it will spark a nice rally into […]
March 18 Biotech Update
Some early weakness but I also suspect today is going to be fairly volatile with the Fed weighing in later this afternoon. So I am really not going to read anything into the price action this morning and even less into the price action in the sector after the announcement. Given how close people think […]
March 2 Biotech Update
A relatively good start to the week with only one slight worry. While the sector is generally green with the market, large cap biotechs are noticeably weaker. While it might not be a major issue if they were less green than some of the small caps, it is odd to see them red with the […]
February 6 Biotech Update
Well, I can honestly say that on Wednesday I did not think the sector would be looking this good on Friday. The economy seems to be improving, the macro (outside of the Greek noise) seems benign, and the sector seems to be shrugging off the hep-C discounts. I am a little surprised but you also […]
January 30 Biotech Update
I want to write this quick to get it out as I spent the morning taking the children to the dentist, so I have a late start. The market is bad (again) but this is really nothing new. This churning is really giving gristle to the bulls and bears. Bears are going to argue it […]
January 26 Biotech Update
It has been a mixed start to the week both in terms of the macro background and also stocks within the sector. It seems like both are looking for new leadership (to the upside or downside) and I still lean towards the next move being higher but it remains a low conviction view. On the […]
January 20 Biotech Update
Not the way you want to start the week with the sector going down with the rest of the market after a weak gap higher. Even more problematic is the severe weakness in the high flying momentum stocks like KITE and BLUE. The fact that these are underperforming can be read as an early warning […]
Revisiting the Bubble Debate
With this week’s moves in the market and with the JP Morgan Healthcare conference finished, I think its time to bring up the debate again about whether or not biotech may be in a bubble. While most are familiar with the outstanding sector performance, lets just put it into context a bit. Since the March […]
January 6 Biotech Update
A good start to the day with the market slightly higher but as always we need to see how they end as yesterday was a rough day and odds are more selling is on its way. That being said the sector held up exceptionally well and was a clear outperformer. I suspect the excitement heading […]
January 2 Biotech Update
It is a good start to the New Year and it is only a matter of time until we start seeing facts talking about years in which the market opened higher end positive X% of the time. In any case, it is nice to see a positive start to the year and it will be […]
Chimera Research Group Catalyst Summary for December 2014
At the end of each month Chimera Research Group provides you with a monthly summary of notable catalysts that have been completed during the past month. DECEMBER 2014: 1) AbbVie (NYSE:ABBV) announced that the FDA approved Viekira Pak (ombitasvir/paritaprevir/ritonavir & dasabuvir), their next generation oral treatment for patients with chronic genotype 1 (GT1) hepatitis C […]
December 22 Biotech Update
It was a weak start to the sector and I suspect that may be a popular start to these notes as the sector seems to have lost some control of pricing power. I am going to spend today talking about the ABBV/ESRX deal as it has significant implications not over for the hep-C market but […]
December 18 Biotech Update
Another rally in the making as we are snapping back from the oversold conditions. It was only a matter of time for this snap but the bigger question is how the market builds upon it. Ideally, this gets the market to new highs with the worst case scenario being we put in a lower high. […]
December 16 Biotech Update
It is a macro world and we only live in it. Short term moves are going to continue to be driven by oil and now Russia and there is not much we can do about but look for the development of bargains. What seems interesting is that the large cap biotechs are underperforming many of […]
December 11 Biotech Update
As I noted yesterday, the market seems to have no memory day to day and despite a bad open and close, the market is higher today as if nothing happened. That is fine as it is also taking the biotech sector higher and there may be some slight outperformance with the SMID names but it […]
